A Label-free Multiplex Electrochemical Biosensor for Detection of Three Breast Cancer Biomarker Proteins Employing Dye/Metal Ions-loaded and Antibodies-Conjugated Polyethyleneimine-Gold Nanoparticles

2021 ◽  
Author(s):  
Kulrisa Kuntamung ◽  
Jaroon Jakmunee ◽  
Kontad Ounnunkad
Keyword(s):  
Breast Cancer ◽  
Electrochemical Biosensor ◽  
Simultaneous Detection ◽  
Growth Factor Receptor ◽  
Cancer Biomarkers ◽  
Electrochemical Immunosensor ◽  
Label Free ◽  
Cancer Antigen ◽  
Breast Cancer Biomarkers ◽  
Epidermal Growth

A new electrochemical immunosensor is developed for the label-free simultaneous detection of mucin1 (MUC1), cancer antigen 15-3 (CA15-3), and human epidermal growth factor receptor 2 (HER2) early breast cancer biomarkers....

scholarly journals Anti-epidermal growth factor receptor conjugated mesoporous zinc oxide nanofibers for breast cancer diagnostics

Nanoscale ◽  
2015 ◽  
Vol 7 (16) ◽  
pp. 7234-7245 ◽  
Author(s):  
Md. Azahar Ali ◽  
Kunal Mondal ◽  
Chandan Singh ◽  
Bansi Dhar Malhotra ◽  
Ashutosh Sharma
Keyword(s):  
Breast Cancer ◽  
Zinc Oxide ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Cancer Diagnostics ◽  
Label Free ◽  
Early Diagnostics ◽  
Breast Cancer Diagnostics ◽  
Epidermal Growth

We report the fabrication of an efficient, label-free, selective and highly reproducible immunosensor with unprecedented sensitivity (femto-molar) to detect a breast cancer biomarker for early diagnostics.

scholarly journals Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR

PLoS ONE ◽  
2021 ◽  
Vol 16 (9) ◽  
pp. e0255580
Author(s):  
Emanuele Caselli ◽  
Cristina Pelliccia ◽  
Valeria Teti ◽  
Guido Bellezza ◽  
Martina Mandarano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dynamic Range ◽  
Mrna Level ◽  
Growth Factor Receptor ◽  
Complementary Method ◽  
Breast Cancer Biomarkers ◽  
Biomarker Testing ◽  
Epidermal Growth ◽  
Computational Pathology ◽  
High Degree

Purpose Decades of quality control efforts have raised the standards of immunohistochemistry (IHC), the principle method used for biomarker testing in breast cancer; however, computational pathology and reverse transcription quantitative PCR (RT-qPCR) may also hold promise for additional substantial improvements. Methods Herein, we investigated discrepancies in the assessment of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and marker of proliferation Ki67 comparing routinely obtained IHC (and FISH) data (ORI) with the results of manual (REV) and semi-automated (DIA) re-evaluation of the original IHC slides and then with RNA expression data from the same tissue block using the MammaTyper® (MT) gene expression assay. Results Correlation for ER and PR was high between ORI IHC and the other three study methods (REV, DIA and RT-qPCR). For HER2, 10 out of 96 discrepant cases can be detected between ORI and REV that involved at least one call in the equivocal category (except for one case). For Ki67, 22 (29.1%) cases were categorized differently by either REV alone (n = 17), DIA alone (n = 15) or both (n = 10) and 28 cases (29.2%) for RT-qPCR. Most of the discrepant Ki67 cases changed from low to high between the original and following assessment and belonged to the intermediate Ki67 expression range (between 9 and 30%). Conclusions Determination of the breast cancer biomarkers ER, PR, HER2 and Ki67 at the mRNA level shows high degree of correlation with IHC and compares well with correlations between original with subsequent independent manual or semi-automated IHC assessments. The use of methods with wider dynamic range and higher reproducibility such as RT-qPCR may offer more precise assessment of endocrine responsiveness, improve Ki67 standardization and help resolve HER2 cases that remain equivocal or ambiguous by IHC/FISH. In summary, our findings seem to configure RT-qPCR as a complementary method to be used in cases of either equivocal results or presenting, at the traditional determination assays, biomarkers expressions close to the cut-off values.

Electrochemical biosensor for simultaneous detection of breast cancer clinically related microRNAs based on a gold nanoparticles/graphene quantum dots/graphene oxide film

The Analyst ◽  
2021 ◽  
Author(s):  
Chammari Pothipor ◽  
Jaroon Jakmunee ◽  
Suwussa Bamrungsap ◽  
Kontad Ounnunkad
Keyword(s):  
Breast Cancer ◽  
Quantum Dots ◽  
Gold Nanoparticles ◽  
Graphene Oxide ◽  
Electrochemical Biosensor ◽  
Graphene Quantum Dots ◽  
Simultaneous Detection ◽  
Carbon Electrode ◽  
Label Free ◽  
Screen Printed Carbon Electrode

A label-free multiplexed electrochemical biosensor based on a gold nanoparticles/graphene quantum dots/graphene oxide (AuNPs/GQDs/GO) modified three-array screen-printed carbon electrode (3SPCE) is successfully constructed to detect miRNA-21, miRNA-155, and miRNA-210 biomarker...

New label-free ultrasensitive electrochemical immunosensor-based Au/MoS2/rGO nanocomposites for CA 27-29 breast cancer antigen detection

2018 ◽  
Vol 42 (13) ◽  
pp. 11046-11053 ◽  
Author(s):  
Nawal A. Alarfaj ◽  
Maha F. El-Tohamy ◽  
Hesham Oraby
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Electrochemical Immunosensor ◽  
Antigen Detection ◽  
Label Free ◽  
Cancer Antigen

Early diagnosis and clinical treatments of breast cancer provide a highly successful chance for patients to survive.

scholarly journals An Electrochemical Aptasensor for the Detection of HER2 as a Breast Cancer Biomarker Based on Gold Nanoparticles-Aptamer Bioconjugates

2021 ◽  
Vol 21 (6) ◽  
pp. 1526
Author(s):  
Yeni Wahyuni Hartati ◽  
Sari Syahruni ◽  
Shabarni Gaffar ◽  
Santhy Wyantuti ◽  
Muhammad Yusuf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Electrostatic Interactions ◽  
Electrochemical Biosensor ◽  
Limit Of Detection ◽  
Growth Factor Receptor ◽  
Covalent Bond ◽  
Redox System ◽  
Dna Aptamer ◽  
Epidermal Growth ◽  
Insight Into

Inaccurate diagnoses contributes to the high mortality rate of breast cancer. Human epidermal growth factor receptor 2 (HER2) is overexpressed in breast cancer tumors at around 20–30%. This study aims to develop an electrochemical biosensor for HER2 based on a gold nanoparticle-aptamer bioconjugate (AuNP@HER2 aptamer) and investigate the interaction between DNA aptamer and HER2 using computational methods. The bioconjugate was synthesized using maleimide and polyethylene glycol as a linker. The –NH2 group of cysteamine that modified the gold electrode can form a covalent bond with the bioconjugate maleimide. The interaction of the bioconjugated aptamer with HER2 was measured electrochemically based on the [Fe(CN)6]3−/4− redox system. The limit of detection, the linear range of HER2, precision, and accuracy in this study were 1.52 ng mL–1, 0.01 to 15.0 ng mL–1, 0.1298, and 94.06%, respectively. The structure of the DNA aptamer was modeled using mFold, Assemble2, and Chimera, with the interaction between the DNA aptamer and HER2 explored by NPDock. The modeling of the aptamer with HER2 showed that electrostatic interactions dominated the attractive forces. The resulting interaction pattern can be used as a template to improve the binding energy of the aptamer, thus providing insight into the development of aptamer-based biosensors.

Sign in / Sign up

Export Citation Format

Share Document